The management of BLT is still evolving because of several advances: [1] the improvement in diagnostic radiological imaging, which should reduce the prevalence of unnecessary liver resections ...

Long classified as a subset of common liver cancer, FLC should be considered its own unique disease. Now researchers are testing a combination drug therapy that targets FLC tumors. Like many rare ...

By Kaplan-Meier analysis, tumor size was a significant predictor of both overall (p = 0.03) and disease-specific (p = 0.02) mortality. However, tumor size approached but did not attain statistical ...

Researchers at the University of Pennsylvania have introduced lab-engineered small extracellular vesicles to target tumors in ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study May Proceed” letter from the FDA. From “Boy Meets World” actress Danielle ...

In liver cancer cells, this results in a massive energy deficiency, the cell cycle is stopped and tumor growth is inhibited. The team also demonstrated this in liver cancer-bearing mice ...

While studying mouse and human liver tumors, they discovered that certain bile acids in the liver could affect the activity of cancer-fighting immune cells, called T cells. The researchers ...

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers, and it has potential with other cancers as well.

Cancer progresses in distinct stages, and understanding this progression is crucial. Early detection significantly increases ...

Scientists have found a way to combat a rare, aggressive form of cancer affecting pregnant women and to better ensure the drug used for the disease reaches tumor cells without damaging healthy tissue.